CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-30 | Glucksmann Alexandra Director | Grant or award | +7,768 | 19,054 | ||
| 2025-05-30 | Glucksmann Alexandra Director | Grant or award · Stock Options (Right to Buy) | +39,815 | 39,815 | ||
| 2025-05-30 | KARABELAS ARGERIS N Director | Grant or award | +7,768 | 19,054 | ||
| 2025-05-30 | KARABELAS ARGERIS N Director | Grant or award · Stock Options (Right to Buy) | +39,815 | 39,815 | ||
| 2025-05-30 | Bennett Jean Director | Grant or award | +7,768 | 19,054 | ||
| 2025-05-30 | Bennett Jean Director | Grant or award · Stock Options (Right to Buy) | +39,815 | 39,815 | ||
| 2025-05-12 | Mills Kenneth T. Director | Option exercise 10b5-1 | +20,602 | $3.76 | $77K | 495,705 |
| 2025-05-12 | Mills Kenneth T. Director | Sale 10b5-1 | −20,602 | $7.91 | $163K | 475,103 |
| 2025-05-12 | Mills Kenneth T. Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −20,602 | 0 | ||
| 2025-03-27 | Mills Kenneth T. Director | Option exercise | +30,752 | $3.76 | $116K | 475,103 |
| 2025-03-27 | Mills Kenneth T. Director | Option exercise · Stock Options (Right to Buy) | −30,752 | 20,602 | ||
| 2025-02-01 | Christmas Patrick J. Chief Legal Officer | Shares withheld for taxes | −4,700 | $8.07 | $38K | 156,110 |
| 2025-02-01 | PAKOLA STEVE Chief Medical Officer | Shares withheld for taxes | −5,263 | $8.07 | $42K | 210,717 |
| 2025-02-01 | Danos Olivier Chief Scientific Officer | Shares withheld for taxes | −5,452 | $8.07 | $44K | 226,348 |
| 2025-01-02 | Simpson Curran Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +478,606 | 478,606 | ||
| 2025-01-02 | PAKOLA STEVE Chief Medical Officer | Shares withheld for taxes | −13,891 | $7.73 | $107K | 151,687 |
| 2025-01-02 | PAKOLA STEVE Chief Medical Officer | Grant or award | +64,293 | 215,980 | ||
| 2025-01-02 | PAKOLA STEVE Chief Medical Officer | Grant or award · Stock Options (Right to buy) | +103,698 | 103,698 | ||
| 2025-01-02 | Danos Olivier Chief Scientific Officer | Shares withheld for taxes | −12,630 | $7.73 | $98K | 172,453 |
| 2025-01-02 | Danos Olivier Chief Scientific Officer | Grant or award | +59,347 | 231,800 |
Page 5 of 11 · 216 trades